Background The Affordable Medicines Facility-malaria (AMFm) is primarily an artemisinin
combination therapy (ACT) subsidy, aimed at increasing availability, affordability, market …

Background Artemisinin combination therapy (ACT) is first-line treatment for malaria in most
endemic countries and is increasingly available in the private sector. Most studies on ACT …

Patients rely on medical care providers to act in their best interests because providers
understand disease pathology and appropriate treatment much better than patients …

Abstract Between 2011 and 2016, the Affordable Medicines Facility-Malaria (AMFm) subsidy
program substantially increased access to WHO prequalified artemisinin combination …

Noncommunicable diseases have become prevalent in low-and middle-income countries. A
key question that remains unresolved is how to support the development of systems to …

Objectives To examine how drug shop clients' expenditures are affected by subsidies for
malaria diagnostic testing and for malaria treatment, and also to examine how expenditures …

Background Most people with febrile illness are treated in the private drug retail sector.
Ghana was among nine countries piloting the Global Fund Affordable Medicines Facility …

Background Many households in sub-Saharan Africa utilize the private sector as a primary
source of treatment for malaria episodes. Expanding access to effective treatment in private …

African countries face special challenges to health-care provision given the current “double
burden” of decreasing effectiveness of tools against traditional tropical diseases and an …

Background Under-five malaria in Nigeria remains one of the biggest threats to global child
health, accounting for 95,000 annual child deaths. Despite having the highest GDP in Africa …